Baxter’s BioScience Business BioScience Facts Baxter’s BioScience business continues its 60-year legacy of providing life-saving and life-sustaining specialty therapies. BioScience treatments share the common connection of improving the lives of patients with rare conditions, chronic diseases or limited treatment options. BioScience Expertise Baxter treatments address a range of critical care disciplines: • Hemophilia therapy – A leading innovator in hemophilia management, Baxter develops recombinant and plasmabased therapies for people with bleeding disorders. • Antibody therapy – Baxter is a leading provider of immunoglobulin therapies for people living with immunodeficiencies and multifocal motor neuropathy. BioScience is one of two major business units at Baxter 2013 BioScience sales reached $6.6 billion The BioScience business operates ten manufacturing facilities in six countries Legacy of Innovation Baxter invests in innovation to continually improve patient outcomes. • Pulmonology therapy – Baxter provides therapies that help treat people who have reduced levels of a blood protein, alpha 1-proteinase inhibitor. Without treatment, the condition can result in early-onset emphysema and premature death. • Biosurgery – Baxter offers biological products and delivery devices used for hemostasis, tissue sealing, adhesion reduction, hard tissue regeneration, as well as soft tissue repair and microsurgery products. First system for separating plasma from whole blood and storing [1941] First commercially produced factor VIII concentrate to treat hemophilia [1968] First product for people with hemophilia who develop antibodies [1977] First genetically engineered recombinant factor VIII [1992] First full-length recombinant factor VIII treatment processed without blood-based additives [2003] • Critical care therapy – Albumin is a plasma-volume expander used to treat burns and maintain fluid volume in critically ill and trauma patients. Baxter is the only company to offer albumin in both glass containers and flexible plastic bags, which weigh less, eliminate the risk of breaking and streamline infusion set up, enabling use in diverse conditions. First albumin in a flexible, plastic container [2005] • Vaccines – Baxter provides vaccines for meningitis C and tick-borne encephalitis. Research & Development Baxter’s BioScience business is supported by a robust research pipeline. The desire to improve lives drives the organization’s R&D priorities, including the development of advanced hemophilia therapies and investigation of treatments for other bleeding disorders; development of treatments for niche conditions within oncology; and discovery and evaluation of biosimilar candidates.